Bayer ’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies

Berlin, January 8, 2024– Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials